MASLD has become the most common chronic liver disease worldwide. The authors review the features of the disease as well as ...

New research highlights a significant link between metabolic dysfunction-associated steatotic liver disease (MASLD), formerly ...

The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...

Often symptomless, fatty liver disease is becoming a leading cause of liver cancer. Learn the role of daily habits, early ...

Medically reviewed by Robert Burakoff, MD Fatty liver disease is a health condition in which fat builds up in the liver. This ...

A new analysis from the Chile BiLS study evaluated the reliability of ultrasound imaging for diagnosing SLD in a high-risk ...

Metabolic dysfunction-associated steatotic liver disease (MASLD), including metabolic dysfunction-associated steatohepatitis (MASH), is the most common aetiology of liver disease worldwide. MASLD is ...

Source Reference: Ochoa-Allemant P, et al "Adverse liver outcomes, cardiovascular events, and mortality in steatotic liver disease" JAMA Intern Med 2025; DOI: 10.1001/jamainternmed.2025.1809.

MASLD is among the most common types of chronic liver disease and is estimated to affect 30% of the global population.

New European guidelines redefine Metabolic dysfunction-associated steatotic liver disease (MASLD) care, offering clearer ...

Dr Kolawole Akande, a consultant gastroenterologist at the University College Hospital (UCH) in Ibadan, in this interview with SADE OGUNTOLA, explains excessive fat in the liver as a dangerous ...